N-((S)-chroman-4-yl)-3-((R)-1-(4,4-diethyl-2-imino-6-oxotetrahydropyrimidin-1(2H)yl)butyl)benzamide

ID: ALA5182418

Chembl Id: CHEMBL5182418

PubChem CID: 166705828

Max Phase: Preclinical

Molecular Formula: C28H36N4O3

Molecular Weight: 476.62

Associated Items:

Names and Identifiers

Canonical SMILES:  CCC[C@H](c1cccc(C(=O)N[C@H]2CCOc3ccccc32)c1)N1C(=N)NC(CC)(CC)CC1=O

Standard InChI:  InChI=1S/C28H36N4O3/c1-4-10-23(32-25(33)18-28(5-2,6-3)31-27(32)29)19-11-9-12-20(17-19)26(34)30-22-15-16-35-24-14-8-7-13-21(22)24/h7-9,11-14,17,22-23H,4-6,10,15-16,18H2,1-3H3,(H2,29,31)(H,30,34)/t22-,23+/m0/s1

Standard InChI Key:  VRULKACKCWLXKD-XZOQPEGZSA-N

Alternative Forms

  1. Parent:

    ALA5182418

    ---

Associated Targets(non-human)

Plasmodium falciparum (966862 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PMX Plasmepsin X (23 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PMIX Plasmepsin IX (10 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 476.62Molecular Weight (Monoisotopic): 476.2787AlogP: 5.10#Rotatable Bonds: 8
Polar Surface Area: 94.52Molecular Species: NEUTRALHBA: 4HBD: 3
#RO5 Violations: 1HBA (Lipinski): 7HBD (Lipinski): 3#RO5 Violations (Lipinski): 1
CX Acidic pKa: CX Basic pKa: 5.38CX LogP: 4.57CX LogD: 4.57
Aromatic Rings: 2Heavy Atoms: 35QED Weighted: 0.49Np Likeness Score: -0.54

References

1. de Lera Ruiz M, Favuzza P, Guo Z, Zhao L, Hu B, Lei Z, Zhan D, Murgolo N, Boyce CW, Vavrek M, Thompson J, Ngo A, Jarman KE, Robbins J, Boddey J, Sleebs BE, Lowes KN, Cowman AF, Olsen DB, McCauley JA..  (2022)  The Invention of WM382, a Highly Potent PMIX/X Dual Inhibitor toward the Treatment of Malaria.,  13  (11.0): [PMID:36385924] [10.1021/acsmedchemlett.2c00355]

Source